Literature DB >> 308036

The class of antibodies sensitizing bacteria measured by mixed reverse passive antiglobulin haemagglutination (MRPAH).

R R Coombs, L Edebo, A Feinstein, B W Gurner.   

Abstract

A test is described which is capable of differentiating and measuring by titration the individual classes of antibody reacting with a bacterial suspension. The serum or fluid under test is incubated with the bacteria which are then very well washed and added to indicator red cells linked with specific antiglobulin reagents. Sensitization of the bacteria by a particular class of antibody is shown by haemagglutination (passive) of the appropriate red cells. Agglutination of the bacteria themselves does not preclude an analysis. The reaction, which has been developed on a brucella system, has been designated Mixed Reverse Passive Antiglobulin Haemagglutination (or MRPAH for short).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 308036      PMCID: PMC1457414     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  10 in total

1.  Use of a 'mixed haemadsorption' method in virus-infected tissue cultures.

Authors:  A FAGRAEUS; A ESPMARK
Journal:  Nature       Date:  1961-04-22       Impact factor: 49.962

2.  Comparison of the direct antiglobulin rosetting reaction with the mixed antiglobulin rosetting reaction for the detection of immunoglobulin on lymphocytes.

Authors:  R R Coombs; A B Wilson; O Eremin; B W Gurner; D G Haegert; Y A Lawson; S Bright; A J Munro
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

3.  Antibody-coated bacteria in the urine and the site of urinary-tract infection.

Authors:  V Thomas; A Shelokov; M Forland
Journal:  N Engl J Med       Date:  1974-03-14       Impact factor: 91.245

4.  Chromic chloride: a coupling reagent for passive hemagglutination reactions.

Authors:  E R Gold; H H Fudenberg
Journal:  J Immunol       Date:  1967-11       Impact factor: 5.422

5.  Specific response of the immunoglobulins to rubella infection.

Authors:  J V Baublis; G C Brown
Journal:  Proc Soc Exp Biol Med       Date:  1968-05

6.  Immunoglobulin class of Brucella antibodies in human sera.

Authors:  W R Kerr; D J Payne; L Robertson; R R Coombs
Journal:  Immunology       Date:  1967-08       Impact factor: 7.397

7.  Structural relationship and complement fixing activity of sheep and other ruminant immunoglobulin G subclasses.

Authors:  A Feinstein; M J Hobart
Journal:  Nature       Date:  1969-08-30       Impact factor: 49.962

8.  Conformation of the free and antigen-bound IgM antibody molecules.

Authors:  A Feinstein; E A Munn
Journal:  Nature       Date:  1969-12-27       Impact factor: 49.962

9.  Serological properties of gamma-A antibodies to Escherichia coli present in human colostrum.

Authors:  M Adinolfi; A A Glynn; M Lindsay; C M Milne
Journal:  Immunology       Date:  1966-06       Impact factor: 7.397

10.  An indirect anti-immunoglobulin rosetting reaction to detect alloantibodies to human lymphocytes.

Authors:  S Bright; A J Munro; Y A Lawson; V C Joysey; R R Coombs
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

  10 in total
  4 in total

1.  IgA anti-gliadin antibodies in coeliac disease.

Authors:  D J Unsworth; M Kieffer; E J Holborow; R R Coombs; J A Walker-Smith
Journal:  Clin Exp Immunol       Date:  1981-11       Impact factor: 4.330

2.  Red-cell IgM-antibody capture assay for the detection of Mycoplasma pneumoniae-specific IgM.

Authors:  R R Coombs; G Easter; P Matejtschuk; T G Wreghitt
Journal:  Epidemiol Infect       Date:  1988-02       Impact factor: 2.451

3.  Studies of Streptococcus suis type 2 infection in pigs.

Authors:  F A Clifton-Hadley
Journal:  Vet Res Commun       Date:  1984-08       Impact factor: 2.459

4.  Human regional tumour lymph nodes: alterations of micro-architecture and lymphocyte subpopulations.

Authors:  O Eremin; P Roberts; D Plumb; J P Stephens
Journal:  Br J Cancer       Date:  1980-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.